Table 4.
Estimated hazard ratio of ovarian cancer prior to the era of targeted therapy
| N | No. of deaths | Adjusted HRb | 95% CI | p-value | |
|---|---|---|---|---|---|
| Age (years) | |||||
| < 40 | 3849 | 988 | ref. | ref. | – |
| 40–59 | 12,169 | 4992 | 1.71 | (1.60–1.84) | <.0001 |
| > 59 | 6862 | 4328 | 3.00 | (2.79–3.22) | <.0001 |
| SEER Stage | |||||
| Early stagea | 6429 | 1113 | ref. | ref. | – |
| Distant stage | 6795 | 3777 | 3.23 | (3.02–3.46) | <.0001 |
| Year of diagnosis | |||||
| 1995–1999 | 3740 | 2230 | ref. | ref. | – |
| 2000–2004 | 4863 | 2671 | 0.89 | (0.84–0.95) | 0.000 |
| 2005–2009 | 6317 | 3227 | 0.94 | (0.85–1.03) | 0.185 |
| 2010–2014 | 7960 | 2180 | 0.73 | (0.65–0.81) | <.0001 |
| Primary treatment | |||||
| With surgery | 19,776 | 8122 | ref. | ref. | – |
| Without surgery | 1772 | 1233 | 1.49 | (1.39–1.58) | <.0001 |
| Histology | |||||
| Serous carcinoma | 10,837 | 5325 | ref. | ref. | – |
| Mucinous carcinoma | 4005 | 1226 | 0.71 | (0.67–0.76) | <.0001 |
| Endometrioid carcinoma | 2191 | 670 | 0.69 | (0.63–0.75) | <.0001 |
| Clear cell carcinoma | 1923 | 507 | 0.80 | (0.73–0.88) | <.0001 |
| Others | 3924 | 2580 | 1.49 | (1.42–1.57) | <.0001 |
aEarly stage: local + regional, HR, hazard ratio; ref., reference; CI, confidence interval; SEER, Surveillance, Epidemiology, and End Results
badjusted for Age, SEER stage, Year of Diagnosis, Primary treatment and Histology